<DOC>
	<DOCNO>NCT02435199</DOCNO>
	<brief_summary>The study consist two period , Screening Period ( ~3 week ) Treatment Period ( 12 week ) . Eligibility study determine Screening test , physical examination/medical history , fulfilment eligibility criterion include assessment pain complete Screening Period . Potential participant require provide write informed consent prior study-specific Screening procedure perform . Following Screening assessment , patient randomize receive either EMA401 300 mg BID placebo . Patient study visit Treatment Period end baseline/randomization visit , end Weeks 3 , 6 , 9 , 12 , assessment .</brief_summary>
	<brief_title>Clinical Trial Designed Determine Safety Efficacy EMA401 Patients With Painful Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Patients Type I Type II diabetes mellitus painful , distal , symmetrical , sensorymotor neuropathy attribute diabetes , least six month duration . Be assess suffer moderate severe pain across Screening Period . The assessment moderate severe pain make use algorithm proprietary Spinifex . The investigator/site staff inform immediately whether patient eligible ineligible ePRO website base patient enter relevant pain score eDiary device . Women child bear potential ( WOCBP ) , must negative urine pregnancy test Screening visit ( Visit 1 ) within 72 hour prior administration IP . Patients take topical treatment PDN time Screening Visit 2 exclude , include lidocaine plaster , capsaicin patch , topical preparation topical medication ( e.g. , aspirin , NonSteroidal AntiInflammatory Drugs ( NSAIDs ) PDN . Have blood pressure reading , rest least five minute , outside systolic blood pressure range 84 151 mmHg diastolic blood pressure &gt; 95 mmHg . If blood pressure outside range , repeat measurement take patient rest . The repeat measurement use screen value . Have serum aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level &gt; 1.5 x upper limit normal total bilirubin concentration &gt; 1.5 x upper limit normal Screening ( Visit 1 ) . Have hemoglobin A1c &gt; 11 % . Known history , positive laboratory result hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection define seropositive hepatitis B surface antigen ( HBsAg ) , HCV antibodies HIV antibody respectively . Have undergone neurolytic neurosurgical therapy use neurostimulating device PDN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>